Flow cytometry is a powerful technology given its ability to analyze the physical and chemical properties of cells and particles.
But many laboratories struggle to find space for advanced flow cytometry cell analyzers.
BD (NYSE:BDX) has responded to that challenge with its benchtop FACSymphony A1 cell analyzer.
BD designed the fluorescence-activated cell analyzer to support modern research demands in a small footprint.
The analyzer can precisely isolate single cells from complex samples. It supports small particle research as well as 16-color immunophenotyping.
The FACSymphony A1 “offers high-end technology and a cost-effective benchtop design,” surmised Thomas E. Polen, BD CEO, in a recent earnings calls.
The FACSymphony A1 cell analyzer supports various types of flow cytometry experiments. In addition, an optional small particle detector enables the analysis of extracellular vesicles.
BD recently debuted its spectral analyzer as well, which is known as the FACSymphony A5 SE.
Filed Under: Drug Discovery and Development, R&D World, RD